country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-187612

Copy Link Print Information

FR-168888 free base

FR-168888 free base is a Na⁺/H⁺ exchanger (NHE) inhibitor (K_i=6.4 nM) with weak inhibitory activity against Na⁺/Ca²⁺ exchanger and no cardioprotective effects. FR-168888 free base is widely applicable to studies related to reperfusion-induced ventricular arrhythmias.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 168620-45-9
Formel: C₁₃H₁₄N₄O₂
Molecular Weight:258.28

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (281 KB)

FR-168888 free base Chemical Structure

CAS. Nr.: 168620-45-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

FR-168888 free base potently inhibits Na⁺/H⁺ exchange in rat thymic lymphocytes and weakly inhibits Na⁺/Ca²⁺ exchange in rat cardiac sarcolemmal vesicles^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Regulation of Cardiac Pump FunctionCardiovascular Regulation

Regulation of Cardiac Pump Function

Cardiovascular Regulation

FR-168888 free base (0.3-10 mg/kg; i.v.; various time points relative to coronary occlusion/reperfusion) reduces the incidence of reperfusion-induced ventricular fibrillation and mortality in anesthetized rats when administered pre-ischemically at 0.3 mg/kg or post-ischemically at doses ≥0.3 mg/kg, with consistent mortality reduction (to 30%) across all post-ischemic 3 mg/kg administration time points^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (male, 250-400 g, myocardial ischemia-reperfusion injury model)^[1]
Dosage:

0.3 mg/kg (pre-ischemic); 0.3 mg/kg (post-ischemic); 1 mg/kg (post-ischemic); 3 mg/kg (post-ischemic); 10 mg/kg (post-ischemic); 3 mg/kg (1 min post-occlusion); 3 mg/kg (immediately before reperfusion)
Administration:

i.v.; 5 min before coronary occlusion; i.v.; 3 min after coronary occlusion; i.v.; 1 min after coronary occlusion; i.v.; immediately before reperfusion
Result:

Reduced reperfusion-induced ventricular fibrillation (VF) incidence to 10% and mortality to 0% (pre-ischemic 0.3 mg/kg).
Reduced VF incidence to 70% and mortality to 50% (post-ischemic 0.3 or 1 mg/kg).
Reduced VF incidence to 60% and mortality to 30% (post-ischemic 3 or 10 mg/kg).
Increased mean blood pressure by 11 mmHg (3 mg/kg) and 10 mmHg (10 mg/kg) 1 minute after administration, and by 9 mmHg (3 mg/kg) and 12 mmHg (10 mg/kg) 2 minutes after administration (post-ischemic 3 or 10 mg/kg).
Reduced mortality to 30% across all post-ischemic 3 mg/kg administration time points.
Reduced VF incidence to 60% (1 min and 3 min post-occlusion) and 30% (immediately before reperfusion) (time-dependent post-ischemic 3 mg/kg).

Related Protocols :

Ca²⁺ Staining Technique

Chemical Information

CAS. Nr. 168620-45-9
Molecular Weight 258.28
Formel C₁₃H₁₄N₄O₂
SMILES

O=C(NC(=N)N)C=1C=C(C=C(C1)CO)N2C=CC=C2
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhu B M, et al. Inhibitory effects of pre-ischemic and post-ischemic treatment with FR 168888, a Na+/H+ exchange inhibitor, on reperfusion-induced ventricular arrhythmias in anesthetized rat[J]. Japanese journal of pharmacology, 2002, 88(1): 93-99.

[2]. F Ohara, et al. Protective effect of FR168888, a new Na+/H+ exchange inhibitor, on ischemia and reperfusion-induced arrhythmia and myocardial infarction in rats: in comparison with other cardioprotective compounds. Jpn J Pharmacol. 1999 Aug;80(4):295-302. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen